Association for Molecular Pathology                       
Newsletter
October 2009, Volume 15, Number 3

Inside this Issue

Front Page
President's Message
Special Features
 AMP Advocacy
 AMP Test Directory
 CHAMP
 JMD Report
 Web Editorial Board
 AMP 2009 Preliminary Program
 AMP 2009 Corporate Workshops

 Announcements
Committee Reports
• Clinical Practice Committee
 Membership & Professional   
  Development Committee
 Nominating Committee
 Professional Relations
  Committee
 Program Committee
 Publications Committee
 Training & Education Committee
Subdivision Reports
 Genetics
 Hematopathology
 Infectious Diseases
 Solid Tumors
2009 AMP Officers and Appointees

Hematopathology Subdivision Report

Kojo S. J. Elenitoba-Johnson, MD By Kojo S. J. Elenitoba-Johnson, MD
Chair, Hematopathology Subdivision
e-mail: kojoelen@umich.edu

We have now finalized the Hematopathology sessions for the 2009 Annual Meeting in Kissimmee, Florida. The program will include discussions involving multiple topics of relevance to the field of Molecular Hematopathology. The Hematopathology sessions will be kicked off by an Early Bird Session on Friday (November 20) given by Dr. Bryan Betz addressing the prognostic implications of acquired mutations in acute myelogenous leukemias.

The Hematopathology Session will include work from AMP members and features five platform (oral) presentations representing a variety of topics ranging from array based karyotyping to detection of diagnostically and prognostically important mutations in hematopoietic malignancies. These presentations selected from a pool of high quality abstracts will be presented at the Meeting, and will be of interest to the Hematopathology community. We are anticipating an exciting and interactive session. 

In the Workshop Acquired Mutations in Myeloproliferative Diseases, Josef Prchal will speak about somatic mutations and uniparental disomy in Philadelphia chromosome negative myeloprolifereative diseases. Rebecca McClure will address practical issues associated with the detection of mutations in JAK2 and other genes in chronic myeloproliferative disorders. The Plenary Sessions will feature work from Laura Pasqualucci discussing the role of mutations genes in the NFκB pathway in the pathogenesis of malignant lymphomas, and Vu Ngo who will discuss the impact of large-scale RNAi Achilles-heel screens in the discovery of pathogenetically-relevant therapeutic targets in diffuse large B-cell lymphoma. 

Overall, we anticipate engaging sessions addressing topical issues with rich educational content. Timothy Greiner and I welcome opportunities to discuss proposals for new initiatives to be considered for future programs in order to continue the tradition of strong molecular Hematopathology sessions at AMP.

In closing, I am grateful to the membership for your confidence in granting me the opportunity to Chair the AMP Hematopathology Subdivision. I look forward to further active participation in our organization and meeting many of you at the Annual Meeting as we hand over the baton to the able Tim Greiner who will serve as your next Chair.